| Bio-inspired engineering of cell-and virus-like nanoparticles for drug delivery A Parodi, R Molinaro, M Sushnitha, M Evangelopoulos, JO Martinez, ... Biomaterials 147, 155-168, 2017 | 241 | 2017 |
| Exosome-like nanovectors for drug delivery in cancer N Arrighetti, C Corbo, M Evangelopoulos, A Pastò, V Zuco, E Tasciotti Current medicinal chemistry 26 (33), 6132-6148, 2019 | 101 | 2019 |
| miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis R El Bezawy, D Cominetti, N Fenderico, V Zuco, GL Beretta, M Dugo, ... Cancer letters 395, 53-62, 2017 | 94 | 2017 |
| Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma R Molinaro, JO Martinez, A Zinger, A De Vita, G Storci, N Arrighetti, ... Biomaterials science 8 (1), 333-341, 2020 | 65 | 2020 |
| Improved Apoptotic Cell Death in Drug-Resistant Non–Small-Cell Lung Cancer Cells by Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Based Treatment L Gatti, G Cossa, S Tinelli, N Carenini, N Arrighetti, M Pennati, ... Journal of Pharmacology and Experimental Therapeutics 348 (3), 360-371, 2014 | 40 | 2014 |
| PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells N Arrighetti, G Cossa, L De Cecco, S Stucchi, N Carenini, E Corna, ... Toxicology and applied pharmacology 310, 9-19, 2016 | 39 | 2016 |
| Drug combinations with HDAC inhibitors in antitumor therapy N Arrighetti, C Corno, L Gatti Critical Reviews™ in Oncogenesis 20 (1-2), 2015 | 32 | 2015 |
| Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and-resistant ovarian carcinoma cells G Cossa, C Lanzi, G Cassinelli, N Carenini, N Arrighetti, L Gatti, E Corna, ... Cancer letters 347 (2), 212-224, 2014 | 30 | 2014 |
| miRNAs as therapeutic tools and biomarkers for prostate cancer N Arrighetti, GL Beretta Pharmaceutics 13 (3), 380, 2021 | 28 | 2021 |
| Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (CC motif) ligand 2-driven signals L Gatti, A Sevko, M De Cesare, N Arrighetti, G Manenti, E Ciusani, ... Oncotarget 5 (12), 4516, 2014 | 28 | 2014 |
| Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma L Gatti, M De Cesare, E Ciusani, E Corna, N Arrighetti, D Cominetti, ... Molecular Pharmaceutics 11 (1), 283-293, 2014 | 19 | 2014 |
| Anionic glycolipids related to glucuronosyldiacylglycerol inhibit protein kinase Akt M Vetro, B Costa, G Donvito, N Arrighetti, L Cipolla, P Perego, ... Organic & Biomolecular Chemistry 13 (4), 1091-1099, 2015 | 18 | 2015 |
| Endosomal escape of polymer‐coated silica nanoparticles in endothelial cells A Parodi, M Evangelopoulos, N Arrighetti, A Cevenini, M Livingston, ... Small 16 (36), 1907693, 2020 | 17 | 2020 |
| A trifunctional self-immolative spacer enables drug release with two non-sequential enzymatic cleavages A Dal Corso, S Arosio, N Arrighetti, P Perego, L Belvisi, L Pignataro, ... Chemical Communications 57 (63), 7778-7781, 2021 | 15 | 2021 |
| Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells C Corno, L Gatti, N Arrighetti, N Carenini, N Zaffaroni, C Lanzi, P Perego Biochemical pharmacology 136, 40-50, 2017 | 15 | 2017 |
| Synergistic interaction of histone deacetylase 6-and MEK-inhibitors in castration-resistant prostate cancer cells C Corno, N Arrighetti, E Ciusani, E Corna, N Carenini, N Zaffaroni, L Gatti, ... Frontiers in Cell and Developmental Biology 8, 610, 2020 | 14 | 2020 |
| Overactive IGF1/insulin receptors and NRASQ61R mutation drive mechanisms of resistance to pazopanib and define rational combination strategies to treat synovial sarcoma C Lanzi, L Dal Bo, E Favini, M Tortoreto, GL Beretta, N Arrighetti, ... Cancers 11 (3), 408, 2019 | 13 | 2019 |
| Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma C Lanzi, E Favini, L Dal Bo, M Tortoreto, N Arrighetti, N Zaffaroni, ... Journal of Experimental & Clinical Cancer Research 40, 1-25, 2021 | 11 | 2021 |
| Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy Y Kazansky, D Cameron, HS Mueller, P Demarest, N Zaffaroni, ... Cancer discovery 14 (6), 965-981, 2024 | 8 | 2024 |
| Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells D Colombo, L Gatti, L Sjöstrand, N Carenini, M Costantino, E Corna, ... Biochemical Pharmacology 197, 114900, 2022 | 7 | 2022 |
Laura GattiFondazione IRCCS Istituto Nazionale Tumori Milano在 istitutotumori.mi.it 的电子邮件经过验证
